Cargando…
Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
α1-Adrenergic receptor antagonists are commonly used to treat male lower urinary tract symptoms and benign prostatic hyperplasia (BPH). We performed a literature search using PubMed, Medline via Ovid, Embase, and the Cochrane Library databases to identify studies on the treatment of BPH by silodosin...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199653/ https://www.ncbi.nlm.nih.gov/pubmed/25328864 http://dx.doi.org/10.2147/RRU.S41618 |
_version_ | 1782339948447268864 |
---|---|
author | Cho, Hee Ju Yoo, Tag Keun |
author_facet | Cho, Hee Ju Yoo, Tag Keun |
author_sort | Cho, Hee Ju |
collection | PubMed |
description | α1-Adrenergic receptor antagonists are commonly used to treat male lower urinary tract symptoms and benign prostatic hyperplasia (BPH). We performed a literature search using PubMed, Medline via Ovid, Embase, and the Cochrane Library databases to identify studies on the treatment of BPH by silodosin. Silodosin is a novel α1-adrenergic receptor antagonist whose affinity for the α1A-adrenergic receptor is greater than that for the α1B-adrenergic receptor. Therefore, silodosin does not increase the incidence of blood pressure-related side effects, which may result from the inhibition of the α1B-adrenergic receptor. Patients receiving silodosin at a daily dose of 8 mg showed a significant improvement in the International Prostate Symptom Score and maximum urinary flow rate compared with those receiving a placebo. Silodosin also improved both storage and voiding symptoms, indicating that silodosin is effective, even during early phases of BPH treatment. Follow-up extension studies performed in the United States, Europe, and Asia demonstrated its long-term safety and efficacy. In the European study, silodosin significantly reduced nocturia compared to the placebo. Although retrograde or abnormal ejaculation was the most commonly reported symptom in these studies, only a few patients discontinued treatment. The incidence of adverse cardiovascular events was also very low. Evidence showing solid efficacy and cardiovascular safety profiles of silodosin will provide a good solution for the treatment of lower urinary tract symptoms associated with BPH in an increasingly aging society. |
format | Online Article Text |
id | pubmed-4199653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41996532014-10-17 Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability Cho, Hee Ju Yoo, Tag Keun Res Rep Urol Review α1-Adrenergic receptor antagonists are commonly used to treat male lower urinary tract symptoms and benign prostatic hyperplasia (BPH). We performed a literature search using PubMed, Medline via Ovid, Embase, and the Cochrane Library databases to identify studies on the treatment of BPH by silodosin. Silodosin is a novel α1-adrenergic receptor antagonist whose affinity for the α1A-adrenergic receptor is greater than that for the α1B-adrenergic receptor. Therefore, silodosin does not increase the incidence of blood pressure-related side effects, which may result from the inhibition of the α1B-adrenergic receptor. Patients receiving silodosin at a daily dose of 8 mg showed a significant improvement in the International Prostate Symptom Score and maximum urinary flow rate compared with those receiving a placebo. Silodosin also improved both storage and voiding symptoms, indicating that silodosin is effective, even during early phases of BPH treatment. Follow-up extension studies performed in the United States, Europe, and Asia demonstrated its long-term safety and efficacy. In the European study, silodosin significantly reduced nocturia compared to the placebo. Although retrograde or abnormal ejaculation was the most commonly reported symptom in these studies, only a few patients discontinued treatment. The incidence of adverse cardiovascular events was also very low. Evidence showing solid efficacy and cardiovascular safety profiles of silodosin will provide a good solution for the treatment of lower urinary tract symptoms associated with BPH in an increasingly aging society. Dove Medical Press 2014-09-26 /pmc/articles/PMC4199653/ /pubmed/25328864 http://dx.doi.org/10.2147/RRU.S41618 Text en © 2014 Cho and Yoo. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Cho, Hee Ju Yoo, Tag Keun Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability |
title | Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability |
title_full | Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability |
title_fullStr | Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability |
title_full_unstemmed | Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability |
title_short | Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability |
title_sort | silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199653/ https://www.ncbi.nlm.nih.gov/pubmed/25328864 http://dx.doi.org/10.2147/RRU.S41618 |
work_keys_str_mv | AT choheeju silodosinforthetreatmentofclinicalbenignprostatichyperplasiasafetyefficacyandpatientacceptability AT yootagkeun silodosinforthetreatmentofclinicalbenignprostatichyperplasiasafetyefficacyandpatientacceptability |